CERo Therapeutics Hldgsの空売り状況は、投資家がCERo Therapeutics Hldgsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

CERo Therapeutics Hldgs (NASDAQ:CERO) 株価情報, 空売り情報

CERo Therapeutics Hldgs

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings, Inc. - Warrants

CERO THERAPEUTICS HOLDINGS INC UNIT 1 CL A & 1/3 WT EXP

B Of A Securities analyst Andrew Obin revised the estimates upward for GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) following the company&#8217;s first-quarter results <a target="_blank" href="https://www.benzinga.com//node/44955951" rel="noreferrer noopener">reported on Wednesday</a>.
The company reported revenue growth of 11% year-over-year to $8.03 billion and +15% organically, beating the consensus of $7.54 billion and EPS of 91 cents, beating&nbsp;the consensus of 53 cents.
GE Vernova reaffirms its 2025 financial outlook, projecting revenue of $36-$37 billion versus the consensus of $37.73 billion and a high-single-digit adjusted EBITDA margin.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/44955817" rel="noreferrer noopener">GE Vernova Posts Strong Q1: Guidance Reflects Limited Tariff Impact, Says Bullish Analyst</a>
The company stated that this guidance accounts for tariffs and inflation, estimated at $300-$400 million, net of mitigating actions.
Obin maintained the 2025 adjusted EBITDA estimate at $3.5 billion (up 73% year-over-year), above the consensus estimate of $3.2 billion.
The analyst&#8217;s projection assumes a 6% year-over-year organic revenue growth and a 360 basis point year-over-year margin expansion.
The positive performance in the first quarter and a favorable tailwind from foreign exchange are expected to help offset the increased net tariff headwinds of $300-400 million, adds the analyst.
For 2026 too, Obin reiterated the adjusted EBITDA estimate at $5.4 billion (up 53% year-over-year), higher than the consensus estimate of $4.5 billion.
The analyst reiterated a Buy rating and a <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44955817/ge-vernova-posts-strong-q1-guidance-reflects-limited-tariff-impact-says-bullish-analyst" rel="noreferrer noopener">price forecast of $485</a>.
Other Ratings:
<ul>
<li>Goldman Sachs analyst reiterated a Buy rating and a price target of $500.</li>
<li>Susquehanna analyst Charles Minervino maintained Vernova a Positive rating and raised the price forecast from $370 to $399.</li>
<li>Baird analyst Ben Kallo kept an Outperform rating and upped the price target from $387 to $405.</li>
</ul>
Price Action: GEV shares closed higher by 7.26% at $360.49&nbsp;on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44995828/texas-instruments-gets-analyst-nod-as-auto-and-industrial-demand-spark-broad-recovery" target="_blank" rel="noreferrer noopener">Texas Instruments Gets Analyst Nod As Auto And Industrial Demand Spark Broad Recovery</a></li>
</ul>
Photo by T. Schneider via Shutterstock

Analyst Color

Equities

Large Cap

News

Price Target

Reiteration

Analyst Ratings

Movers

Trading Ideas

GE Vernova To Navigate Tariffs, Analyst Sees Forex Gains Offsetting Headwinds

Rumors

GOOG

GOOGL

Alphabet CEO Reportedly Says AI Overviews Reached Over 1.5B Monthly Users, During Conference Call

Under the terms of the merger agreement, which has been unanimously adopted by both boards of directors, shareholders of HarborOne will receive for each share of HarborOne common stock, at the holder's election, either (i) 0.765 shares of Eastern common stock (the "Stock Consideration") or (ii) $12.00 in cash (the "Cash Consideration"), subject to allocation procedures to ensure that the total number of shares of HarborOne common stock that receive the Stock Consideration represents between 75% and 85% of the total number of shares of HarborOne common stock outstanding immediately prior to the completion of the merger. The transaction is intended to qualify as a tax-free reorganization for federal income tax purposes and to provide a tax-free exchange for HarborOne shareholders for the Stock Consideration they will receive. Assuming 80% Stock Consideration, the midpoint of the range, Eastern anticipates issuing approximately 25.2 million shares of its common stock and paying an aggregate amount of $99 million in cash in the merger. Based upon Eastern's $15.48 per share closing price on April 23, 2025, the transaction is valued at approximately $490 million.
 &nbsp;

HONE

Eastern Bankshares And HarborOne Bancorp Enter Merger Agreement; HarborOne Shareholders to Receive Either 0.765 Shares Of Eastern Or $12 In Cash, Subject To Allocation Procedures

Richmond Mutual Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBI#NASDAQ">RMBI</a>) reported quarterly earnings of $0.20 per share. This is a 13.04 percent decrease over earnings of $0.23 per share from the same period last year.

Earnings

RMBI

Richmond Mutual Bancorp Q1 EPS $0.20 Down From $0.23 YoY

Guidance

Ring Energy Reduced Capital spending Guidance Range With A Midpoint Decrease Of Over 50% To $18M, Reaffirmed Guidance Range For Oil And Total Sales Volumes

Hilltop Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTH#NYSE">HTH</a>) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.54 by 20.37 percent. This is a 54.76 percent increase over earnings of $0.42 per share from the same period last year. The company reported quarterly sales of $105.12 million which beat the analyst consensus estimate of $103.32 million by 1.74 percent. This is a 1.44 percent increase over sales of $103.62 million the same period last year.

Earnings Beats

Hilltop Hldgs Q1 GAAP EPS $0.65 Beats $0.54 Estimate, Sales $105.12M Beat $103.32M Estimate

OP Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPBK#NASDAQ">OPBK</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.32 by 15.62 percent. This is a 8.82 percent increase over earnings of $0.34 per share from the same period last year.

OPBK

OP Bancorp Q1 EPS $0.37 Beats $0.32 Estimate

Seacoast Banking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBCF#NASDAQ">SBCF</a>) reported quarterly earnings of $0.38 per share which missed the analyst consensus estimate of $0.40 by 5 percent. This is a 2.7 percent increase over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $140.70 million which beat the analyst consensus estimate of $137.87 million by 2.05 percent. This is a 12.04 percent increase over sales of $125.58 million the same period last year.

Earnings Misses

SBCF

Seacoast Banking Q1 Adj. EPS $0.38 Misses $0.40 Estimate, Sales $140.70M Beat $137.87M Estimate

WIIM

Celestica shares are trading lower after the company issued Q2 sales guidance below estimates.

Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) reported first-quarter financial results after the market close on Thursday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/04/b44994498/intel-reports-first-quarter-2025-financial-results">from the quarter</a>.
Q1 Earnings: Intel reported first-quarter revenue of $12.67 billion, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $12.3 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The chipmaker reported first-quarter adjusted earnings of 13 cents per share, beating analyst estimates of one cent per share. 
Total revenue growth in the first quarter was flat on a year-over-year basis. Here&#8217;s a breakdown of revenue by category. 
<ul>
<li>Client Computing Group: $7.6 billion, down 8% year-over-year</li>
</ul>
<ul>
<li>Data Center and AI: $4.1 billion, up 8% year-over-year</li>
</ul>
<ul>
<li>Total Intel Products: $11.8 billion, down 3% year-over-year</li>
</ul>
<ul>
<li>Intel Foundry: $4.7 billion, up 7% year-over-year</li>
</ul>
<ul>
<li>All Other: $900 million, up 47% year-over-year</li>
</ul>
Intel said it generated $800 million in cash from operations during the quarter. The company ended the period with approximately $8.95 billion in cash and cash equivalents.
&#8220;The&nbsp;first quarter&nbsp;was a step in the right direction, but there are no quick fixes as we work to get back on a path to gaining market share and driving sustainable growth,&#8221; said&nbsp;Lip-Bu Tan, CEO of Intel. 
&#8220;I am taking swift actions to drive better execution and operational efficiency while empowering our engineers to create great products. We are going back to basics by listening to our customers and making the changes needed to build the new Intel.&#8221;
Intel said it&#8217;s taking actions to become more efficient, including streamlining the organization, eliminating management layers and enabling faster decision-making. There was no specific figure regarding workforce reductions, but reports from earlier this week indicated that the company planned to cut 20% of employees.
Tan&nbsp;<a href="https://www.benzinga.com/25/03/44555938/intels-new-ceo-refuses-to-sugarcoat-the-companys-2024-performance-vows-to-align-spending-with-market-demand" target="_blank" rel="noreferrer noopener">referenced previous workforce reductions</a>&nbsp;in an inaugural letter to shareholders after he took the reins of Intel last month. The new CEO has been tasked with turning around Intel, which has lost ground to competitors in recent years, falling behind major players like&nbsp;Nvidia&nbsp;in the AI race.
Outlook: Intel said Thursday that it planned to cut 2025 operating expenses to $17 billion. The company also forecasted 2026 operating expenses of $16 billion.
Intel expects second-quarter revenue to be in the range of $11.2 billion to $12.4 billion versus estimates of $12.84 billion. The company anticipates a second-quarter earnings loss of 32 cents per share versus estimates for a loss of 16 cents per share. 
The weak guidance appears to be weighing on shares after-hours.
Intel executives will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET.
INTC Price Action: <a href="http://benzinga.com/quote/intc" target="_blank" rel="noreferrer noopener">Intel shares</a> were down 6.05% after-hours, trading at $20.34 at the time of publication Wednesday. The chip stock is now down about 39% over the past year, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44971572/nvidia-chip-ban-wont-stop-chinas-ai-momentum-say-analysts-blocking-h20-would-hand-market-to-huawei-amid-trump-era-export-crackdown">Nvidia Chip Ban Won&#8217;t Stop China&#8217;s AI Momentum, Say Analysts — Blocking H20 Would Hand Market To Huawei Amid Trump-Era Export Crackdown</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/europe">Tupungato</a>/Shutterstock.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534; WATCH LIVE: Intel Q1 2025 Earnings Call &#x7C; $INTC" width="500" height="281" src="https://www.youtube.com/embed/Gm28clo6y0Q?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

After-Hours Center

Tech

INTC

Intel Q1 Earnings: Revenue Beat, EPS Beat, Shares Tumble On Weak Guidance, Chipmaker Plans 'Swift Actions' To Drive Efficiency

Heritage Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTBK#NASDAQ">HTBK</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.18 by 5.56 percent. This is a 11.76 percent increase over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $46.06 million which beat the analyst consensus estimate of $44.28 million by 4.01 percent. This is a 9.29 percent increase over sales of $42.14 million the same period last year.

HTBK

Heritage Commerce Q1 EPS $0.19 Beats $0.18 Estimate, Sales $46.06M Beat $44.28M Estimate

DIVIDENDS AND SHARE REPURCHASES
The Company's Board of Directors declared a quarterly cash dividend of $0.13 per common share, representing a $0.01, or 8%, increase. The dividend will be payable on June 16, 2025 to shareholders of record as of the close of business on June 3, 2025.
The Company repurchased 2,875,530 shares of common stock during the first quarter at a weighted average price of $16.62, for an aggregate purchase price of $48.7 million.

Dividends

Eastern Bankshares Increases Quarterly Dividend From $0.12 To $0.13 Per Share

Trading Halt: Halted at 4:40:00 p.m. ET - Trading Halt: Halt News Pending

HarborOne Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HONE#NASDAQ">HONE</a>) reported quarterly earnings of $0.14 per share which missed the analyst consensus estimate of $0.17 by 17.65 percent. This is a 17.65 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $31.47 million which missed the analyst consensus estimate of $32.35 million by 2.74 percent. This is a 2.90 percent increase over sales of $30.58 million the same period last year.

HarborOne Bancorp Q1 EPS $0.14 Misses $0.17 Estimate, Sales $31.47M Miss $32.35M Estimate

Cantor Equity Partners Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEP#NASDAQ">CEP</a>) were trading higher Thursday following news that the company will merge with a newly formed Bitcoin-focused entity called <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44975441/cantor-fitzgerald-backed-twenty-one-launches-strategy-rival-at-3-billion-valuation">Twenty One. </a>
What To Know: The deal, announced on April 24, 2025, values the new venture at $3.6 billion and positions it as the third-largest public holder of Bitcoin globally, after MicroStrategy and Tether.
The transaction is backed by major crypto and tech players including Tether, SoftBank Group and Jack Mallers, who will serve as CEO of Twenty One. Tether and Bitfinex will retain majority ownership, while SoftBank will hold a substantial minority stake. The merged entity will control approximately 42,000 Bitcoin and intends to increase its holdings further.
In addition to the merger, Twenty One has raised $585 million in fresh capital — $385 million via convertible senior secured notes and $200 million in equity. The funds will primarily be used to purchase additional Bitcoin and support general operations. Tether has committed to acquiring the Bitcoin before the deal officially closes.
Twenty One will focus on Bitcoin-native financial tools, such as lending platforms and performance metrics like &#8220;Bitcoin Per Share&#8221; and &#8220;Bitcoin Return Rate.&#8221; The company also plans to build Bitcoin-centric media content and capital markets products. It aims to be a pure-play public vehicle for Bitcoin accumulation and adoption, diverging from traditional financial reporting standards by emphasizing Bitcoin ownership per share over fiat earnings.
Following the merger, shares will trade under the ticker "XXI" on Nasdaq. Until then, Cantor Equity Partners will continue trading as "CEP." The transaction is still subject to shareholder approval and customary closing conditions.
CEP Price Action: Cantor Equity Partner shares closed Thursday up 50.30% at $24.80, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="555" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24145421/Screenshot-2025-04-24-at-14.54.04-1024x555.png" alt="" class="wp-image-887411" style="width:444px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24145421/Screenshot-2025-04-24-at-14.54.04-1024x555.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24145421/Screenshot-2025-04-24-at-14.54.04-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24145421/Screenshot-2025-04-24-at-14.54.04-768x416.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24145421/Screenshot-2025-04-24-at-14.54.04.png 1510w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44988781/wall-street-rally-extends-into-third-day-whats-driving-markets-thursday">Wall Street Rally Extends Into Third Day: What&#8217;s Driving Markets Thursday?</a></li>
</ul>
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Cantor Equity Partners Shares Nearly Double: What's Going On?

Eastman Chemical shares are trading lower after the company reported worse-than-expected Q1 sales results and issued Q2 adjusted EPS guidance below estimates.

Rhinebeck Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBKB#NASDAQ">RBKB</a>) reported quarterly earnings of $0.21 per share. This is a 110 percent increase over earnings of $0.10 per share from the same period last year.

RBKB

Rhinebeck Bancorp Q1 EPS $0.21 Up From $0.10 YoY

APPF

AppFolio shares are trading lower after the company reported Q1 financial results and missed its adjusted EPS and revenue estimates.

OceanFirst Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCFC#NASDAQ">OCFC</a>) reported quarterly earnings of $0.35 per share which met the analyst consensus estimate. This is a 20.45 percent decrease over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $86.65 million which beat the analyst consensus estimate of $83.94 million by 3.23 percent. This is a 0.50 percent increase over sales of $86.22 million the same period last year.

OCFC

OceanFirst Financial Q1 Adj. EPS $0.35, Inline, Sales $86.65M Beat $83.94M Estimate

SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) affirms FY2025 GAAP EPS guidance from $3.00-$3.10 to $3.00-$3.10 vs $3.09 analyst estimate..

SLM Affirms FY2025 GAAP EPS Guidance of $3.00-$3.10 vs $3.09 Est

Press Releases

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

CERo Therapeutics Holdings, Inc.  Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236

Contracts

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERO

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Alzamend Neuro

180 Life Sciences

Azitra

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Galecto

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Oragenics

Palisade Bio

Palatin Techs

SILO Pharma

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Theriva Biologics

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

Longevity Health Holdings, Inc. - Common Stock

Comments

CERo Therapeutics Hldgs

空売り

CERo Therapeutics Hldgs (NASDAQ:CERO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル